User login

We offer our registered users tailored information, free online courses and exclusive content.

You have an old EXCEMED account ...

Our platform has been renewed. All users registered at any of the old websites are kindly requested to reset their password. Why is this?

... or you lost your password?

International guidelines in thyroid disease in daily practice

International guidelines in thyroid disease in daily practice
  • Endocrinology and metabolism
  • Thyroid disorder
Symposium by Excemed
Friday, Jun 8 - Saturday, Jun 9 2012
Vienna, Austria

Accreditation

EACCME®
Registration status
Closed

Overview

Thyroid disorders are among the most commons encountered  in the endocrinological practice. In the Colorado study (US), 9.4% of subjects had high TSH concentration, with higher frequency found in women than in men. There is no unanimity of opinion among specialists regarding the need for thyroid screening, or in the approach to treatment of hypothyroidism, especially whether or not subclinical hypothyroidism should be treated. Also, there is still controversy if women who desire pregnancy should be screened for thyroid diseases and whether or not they should be treated in borderline situations.

Thyroid nodules are common, with an estimated prevalence ranging from 3% to 7% on the basis of palpation. From 20% to 48% of patients with one palpable thyroid nodule are found to have additional nodules when investigated by ultrasound.

The American Cancer Society estimates that thyroid cancer incidence is increasing by approximately 6% per year. Scientific thyroid societies over the world have updated their recommendations for the evaluation and management of thyroid disorders, nodules and cancer, and these topics will be addressed

This conference, hosted by Serono Symposia International Foundation, will represent a unique opportunity to confront different experiences from several well-recognized experts in Europe. The main objective of the meeting will be to critically review recently published international guidelines in thyroid disorders and to address potential controversies in daily practice.

Learning objectives

After attending this conference, participants will have up-to-date knowledge on thyroid diseases and will be able to:

  • Incorporate recent guidelines in the daily management of thyroid disorders
  • Apply the most recent evidence in screening and management of thyroid disorders to the general population and in pregnancy
  • Assess the short comings of new guidelines in thyroid diseases
  • Carefully assess the clinical relevance of subclinical thyroid disease
  • Evaluate the role of newer therapies in the management of thyroid cancer

Accreditation details

Serono Symposia International Foundation (www.seronosymposia.org) is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net

The Conference “International guidelines in thyroid disease in daily practice” (June 8-9, 2012, Vienna, Austria) is designated for a maximum of 9 (nine) hours of European CME credits (ECMEC). Each medical specialist should claim only those credits that he/she actually spent in the educational activity. EACCME credits are recognized by the American Medical Association (AMA) towards the Physician’s Recognition Award (PRA). To convert EACCME credit to AMA PRA category 1 credit, please contact the AMA.

Additional information

Learning effectiveness project

Serono Symposia International Foundation is conducting a Learning Effectiveness Project at meetings during 2012. The meeting 'International guidelines in thyroid disease  has been chosen to participate in this project.

Scientific programme

Friday, June 8

 

Session I: Hyperthyroidism / thyroid autoimmunity

 

Session Chairman: G J Kahaly, Germany

14.30 L1: Genetics vs. environment in autoimmune thyroid disease
T Bednarczuk, Poland

15.00 L2: TSH receptor autoantibodies: Differentiation and clinical relevance
P D Olivo, USA

15.30 L3: Guidelines for the management of Graves‘ hyperthyroidism
R Bahn, USA

16.30 L4: Consensus management of Graves‘ orbitopathy
L Bartalena, Italy

17.00 L5: Cardiac involvement in Graves’ vs. nonautoimmune hyperthyroidism
B Biondi, Italy

17.30 L6: Thyroid autoimmunity and pregnancy
K Poppe, Belgium Video presentation

Saturday, June 9

 

Session II Hypothyroidism / Thyroid nodules

 

Session Chairman: A Pinchera, Italy

09.00 L7: New guidelines for the management of thyroid dysfunction during pregnancy
J H Lazarus, United Kingdom Video presentation

09.30 L8: Cardiovascular risks of subclinical hypothyroidism
S Pearce, United Kingdom

10.00 L9: New European guidelines for the treatment of hypothyroidism
B Nygaard, Denmark

11.00 L10: Guidelines for diagnosis of thyroid nodules

P Vitti, Italy

11.30 L11: Guidelines for the treatment of thyroid nodules
J L Wemeau, France

12.00 L12: New treatment modalities of thyroid nodules
L Hegedus, Denmark

 

Session III Thyroid cancer

 

Session Chairman: J Orgiazzi, France

14.00 L13: Surgery for thyroid cancer: State of the Art
H Dralle, Germany

14.30 L14: Management of differentiated thyroid cancer
S Leboulleux ,France

15.00 L15: Management of medullary thyroid cancer
B Jarzab, Poland

16.00 L16: Ultrasonography guidelines for the follow-up of thyroid cancer
L Leenhardt, France

16.30 L17: Management of metastatic / poor prognosis forms of thyroid cancer / new targeted therapies
L Groussin, France

17.00 L18: Pitfalls: Interesting cases of differentiated thyroid cancer
M Alevizaki, Greece

CME provider

Luigi Bartalena

Department of Clinical and Experimental Medicine

University of Insubria

Varese, Italy

George J. Kahaly

Department of Medicine I

Gutenberg University Medical Center

Mainz, Germany

Jacques Orgiazzi

Service d’endocrinologie-diabétologie-maladies métaboliques

Hospices Civils de Lyon

Centre hospitalier Lyon-Sud, Université Lyon 1

Pierre-Bénite, France

Simon Pearce

Institute of Human Genetics

International Centre for Life

Newcastle upon Tyne, UK

Chair(s)

George J. Kahaly

Professor of Medicine and Endocrinology / Metabolism, Chief of the endocrine outpatient clinic
Dept of Medicine
Gutenberg University Medical Center
Mainz, Germany

Jacques Orgiazzi

Service d’endocrinologie-diabétologie-maladies métaboliques
Hospices Civils de Lyon, Centre hospitalier Lyon-Sud
Université Lyon 1
Pierre-Bénite, France

Faculty

Serono Symposia International Foundation adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME) and all other professional organizations, as applicable, which state that programs awarding continuing education credits must be balanced, independent, objective, and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices, and other products (other than those uses indicated in approved product labeling/package insert for the product) may be presented in the program (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter). We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so participants may form their own judgments, based on full disclosure of the facts. Further all opinions and recommendations presented during the program and all program-related materials neither imply an endorsement, nor a recommendation, on the part of Serono Symposia International Foundation. All presentations solely represent the independent views of the presenters/authors.The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non-EMEA/FDA approved (off-label) uses of drugs:

Maria Alevizaki: Declared no potential conflict of interest

Rebecca S. Bahn: Declared no potential conflict of interest

Luigi Bartalena: Declared his presentation includes discussion of the potential use of rituximab for Graves’ orbitopathy.

Sabina Baumgartner-Parzer: Declared no potential conflict of interest

Bernadette Biondi: Declared no potential conflict of interest

Tomasz Bednarczuk: Declared no potential conflict of interest

Henning Dralle: Declared no potential conflict of interest

Lionel Groussin: Declared no potential conflict of interest

Laszlo Hegedüs: Declared receipt of honoraria from Genzyme, Novo Nordisk and Theraction. Declared to be member of Genzyme, Novo Nordisk and Theraction advisory boards and to be a stakeholder in Theraction

Barbara Jarzab: Declared receipt of consultation fees from Astra Zeneca and to be member of the Astra Zeneca advisory board

George J. Kahaly: Declared no potential conflict of interest

John H. Lazarus: Declared no potential conflict of interest

Sophie Leboulleux: Declared receipt of honoraria from Genzyme

Laurence Leenhardt: Declared no potential conflict of interest

Birte Nygaard: Declared no potential conflict of interest

Paul D. Olivo: Declared to be an employee of Quidel corporation

Jacques Orgiazzi: Declared receipt of honoraria from Merck Serono

Simon H.S. Pearce: Declared to be member of GSK advisory board and of Merck-Serono ETA-2011, Krakow

Aldo Pinchera: Declared no potential conflict of interest

Kris Poppe: Declared receipt of honorariafrom Merck-Serono ETA-2011, Krakow

Paolo Vitti: Declared no potential conflict of interest

Jean Luis Wémeau: Declared no potential conflict of interest